



www.genfit.com

GENFIT REACTION TO SUDDEN STOCK PRICE MOVEMENT

Lille (France), Boston (Massachusetts, United States), June 19, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today reacts to the sudden decrease of its stock price on June 18.

The company noted yesterday a large volume of transactions which led to a very significant decrease of its stock price. No results neither scientific, commercial, nor financial can be associated to justify this movement. The clinical studies in progress are advancing in perfect expectations of the company. The partnering discussions in progress on the different programs are in phase with the strategy and development of the company, and are advancing without any interruption.

The company thus thinks that the publication of an outdated target stock price by the company Invest Securities is at the origin of the exceptional downward trend.

The company Invest Securities and their financial analyst regret this situation and consider that the previous stock target price provided (2,60€) is totally void and that it will be revised with knowledge of the latest information on the company; and notably in consideration of the present cash position which has become very favorable due to the funds raised since the beginning of year 2013.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board

Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr